HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus

Elias K. Halvas, Kevin W. Joseph, Leah D. Brandt, Shuang Guo, Michele D. Sobolewski, Jana L. Jacobs, Camille Tumiotto, John Bui, Joshua C. Cyktor, Brandon F. Keele, Gene D. Morse, Michael J. Bale, Wei Shao, Mary F. Kearney, John M. Coffin, Jason W. Rausch, Xiaolin Wu, Stephen H. Hughes, John W. MellorsJournal of Clinical Investigation 2020 · DOI

Abstract

BACKGROUND: HIV-1 viremia that is not suppressed by combination antiretroviral therapy (ART) is generally attributed to incomplete medication adherence and/or drug resistance. We evaluated individuals referred by clinicians for nonsuppressible viremia (plasma HIV-1 RNA above 40 copies/mL) despite reported adherence to ART and the absence of drug resistance to the current ART regimen.

METHODS: Samples were collected from at least 2 time points from 8 donors who had nonsuppressible viremia for more than 6 months. Single templates of HIV-1 RNA obtained from plasma and viral outgrowth of cultured cells and from proviral DNA were amplified by PCR and sequenced for evidence of clones of cells that produced infectious viruses. Clones were confirmed by host-proviral integration site analysis.

RESULTS: HIV-1 genomic RNA with identical sequences were identified in plasma samples from all 8 donors. The identical viral RNA sequences did not change over time and did not evolve resistance to the ART regimen. In 4 of the donors, viral RNA sequences obtained from plasma matched those sequences from viral outgrowth cultures, indicating that the viruses were replication competent. Integration sites for infectious proviruses from those 4 donors were mapped to the introns of the MATR3, ZNF268, ZNF721/ABCA11P, and ABCA11P genes. The sizes of the clones were estimated to be from 50 million to 350 million cells.

CONCLUSION: These findings show that clones of HIV-1-infected cells producing virus can cause failure of ART to suppress viremia. The mechanisms involved in clonal expansion and persistence need to be defined to effectively target viremia and the HIV-1 reservoir.

Introduction

For most people living with HIV, combination antiretroviral therapy (ART) is a lifesaver, suppressing the virus to undetectable levels. However, clinicians occasionally encounter "nonsuppressible viremia," where low levels of the virus remain detectable in the plasma despite the patient strictly following their treatment and the virus showing no signs of drug resistance.

Traditionally, doctors assumed these patients were either missing doses or that the virus had found a way to replicate despite the drugs. This study investigates whether this persistent virus actually originates from a stable, "active" reservoir: clones of infected cells that have proliferated, creating a massive factory of identical viruses that current ART (which prevents new infections but doesn't stop existing infected cells from producing virus) cannot shut down.

Methods and Datasets

The researchers studied eight donors experiencing nonsuppressible viremia for over six months. They employed a suite of high-precision molecular techniques:

  • Single-Genome Sequencing (SGS): Unlike standard sequencing, which averages out a population, SGS looks at individual viral templates. This allowed the team to identify groups of 100% identical viral sequences, a hallmark of clonal origin.
  • Quantitative Viral Outgrowth Assay (qVOA): This determines if the virus found in a patient's cells is "replication-competent" (capable of infecting new cells) rather than just being a broken genetic fragment.
  • Integration Site Analysis (ISA): HIV inserts its DNA into the host cell's genome at a random location. If two cells have the virus at the exact same chromosomal coordinate, they are confirmed to be descendants of the same original infected cell—a clone.
  • Near-Full-Length (NFL) Sequencing: The team sequenced nearly the entire 9,000-base HIV genome to ensure the viruses were truly intact and identical.

The study relied on primary clinical samples (plasma and PBMCs) from 8 human donors. Genetic data was compared against GenBank for viral sequence comparison and the UCSC Genome Browser (hg19) to map the exact "addresses" where the virus integrated into human DNA.

Key Results: The "Repliclone"

The authors demonstrate that some T cell clones are not just carrying the virus (latent), but are actively producing infectious virions. They termed these "repliclones." In all 8 donors, the viral sequences in the blood remained identical over time. If the virus were actively replicating (infecting new cells), it would inevitably mutate and evolve. The lack of change proves the virus is simply being "shed" from a stable clonal source.

Figure 3: Phylogenetic tree for Donor C-02 showing identical sequences across plasma, DNA, and viral outgrowth, with the integration site mapped to the MATR3 gene.

These aren't small clusters of cells; the researchers estimated the sizes of these clones to be between 50 million and 350 million cells. In the four donors with infectious clones, the virus was found in the introns of specific genes (MATR3, ZNF268, ZNF721/ABCA11P, and ABCA11P).

Phylogenetic tree for Donor F-07, demonstrating another instance of a large infectious clone integrated into the ZNF721 gene.

Identical HIV-1 RNA was found in the plasma of all 8 donors, making up a median of 58.6% of their total viral population. In 4 out of 8 donors, the identical sequences in the plasma matched the sequences of viruses that grew in lab cultures, proving the clones were producing fully functional, infectious HIV. This explains why changing ART regimens often fails to suppress this low-level viremia—the drugs are blocking a door (new infection) that the virus isn't even using.

Limitations and Future Work

The study is limited by a small cohort (8 donors), though the depth of analysis per donor is significant. A major remaining mystery is why these specific infected cells expand into such massive clones. Is it driven by the body's response to a common infection (like CMV), or does the location of the virus in the human genome give that specific cell a survival advantage?

Future work will need to identify therapies that can specifically target and eliminate these large "repliclones," as they represent a significant barrier to a functional HIV cure and a potential source of viral rebound if ART is ever stopped.

Summary updated

Abstract

BACKGROUNDHIV-1 viremia that is not suppressed by combination antiretroviral therapy (ART) is generally attributed to incomplete medication adherence and/or drug resistance. We evaluated individuals referred by clinicians for nonsuppressible viremia (plasma HIV-1 RNA above 40 copies/mL) despite reported adherence to ART and the absence of drug resistance to the current ART regimen.METHODSSamples were collected from at least 2 time points from 8 donors who had nonsuppressible viremia for more than 6 months. Single templates of HIV-1 RNA obtained from plasma and viral outgrowth of cultured cells and from proviral DNA were amplified by PCR and sequenced for evidence of clones of cells that produced infectious viruses. Clones were confirmed by host-proviral integration site analysis.RESULTSHIV-1 genomic RNA with identical sequences were identified in plasma samples from all 8 donors. The identical viral RNA sequences did not change over time and did not evolve resistance to the ART regimen. In 4 of the donors, viral RNA sequences obtained from plasma matched those sequences from viral outgrowth cultures, indicating that the viruses were replication competent. Integration sites for infectious proviruses from those 4 donors were mapped to the introns of the MATR3, ZNF268, ZNF721/ABCA11P, and ABCA11P genes. The sizes of the clones were estimated to be from 50 million to 350 million cells.CONCLUSIONThese findings show that clones of HIV-1-infected cells producing virus can cause failure of ART to suppress viremia. The mechanisms involved in clonal expansion and persistence need to be defined to effectively target viremia and the HIV-1 reservoir.FUNDINGNational Cancer Institute, NIH; Howard Hughes Medical Research Fellows Program, Howard Hughes Medical Institute; Bill and Melinda Gates Foundation; Office of AIDS Research; American Cancer Society; National Cancer Institute through a Leidos subcontract; National Institute for Allergy and Infectious Diseases, NIH, to the I4C Martin Delaney Collaboratory; University of Rochester Center for AIDS Research and University of Rochester HIV/AIDS Clinical Trials Unit.
BibTeX
@article{halvas2020hiv,
  author = {Elias K. Halvas and Kevin W. Joseph and Leah D. Brandt and Shuang Guo and Michele D. Sobolewski and Jana L. Jacobs and Camille Tumiotto and John Bui and Joshua C. Cyktor and Brandon F. Keele and Gene D. Morse and Michael J. Bale and Wei Shao and Mary F. Kearney and John M. Coffin and Jason W. Rausch and Xiaolin Wu and Stephen H. Hughes and John W. Mellors},
  title = {{HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus}},
  journal = {Journal of Clinical Investigation},
  year = {2020},
  doi = {10.1172/jci138099},
}
Figure